stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Return on equity
Xenon Pharmaceuticals Inc.'s return on equity over the twelve months to 30 June 2026 was −43.6%, up 8.1 percentage points from fiscal 2025 (−51.8%). Over the past ten years it has ranged from −61.5% (fiscal 2017) to −19.8% (fiscal 2022); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −51.8% | (23.91) |
| FY2024 | −27.9% | (5.73) |
| FY2023 | −22.1% | (2.35) |
| FY2022 | −19.8% | 2.07 |
| FY2021 | −21.8% | 0.76 |
| FY2020 | −22.6% | 21.92 |
| FY2019 | −44.5% | 3.57 |
| FY2018 | −48.1% | 13.42 |
| FY2017 | −61.5% | (24.70) |
| FY2016 | −36.8% | (13.27) |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | 31.4% |
| PBLS Parabilis Medicines, Inc. compare | 0.00% |
| ABCL AbCellera Biologics Inc. compare | −17.3% |
| TNGX Tango Therapeutics, Inc. compare | −21.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | −29.1% |
| RLAY Relay Therapeutics, Inc. compare | −36.8% |
| IRON Disc Medicine, Inc. compare | −39.1% |
| XENE Xenon Pharmaceuticals Inc. | −43.6% |
| VKTX Viking Therapeutics, Inc. compare | −96.4% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Altman Z-score
- The full statement